The epidemiology of bacterial meningitis has changed as a result of the widespread use of
conjugate vaccines and preventive antimicrobial treatment of pregnant women. Given the …

Reports of illness resembling meningococcal disease date back to the 16th century. The
description reported by Vieusseux in 1805 is generally thought to be the first definitive …

Background An effective, affordable, multivalent meningococcal conjugate vaccine is
needed to prevent epidemic meningitis in the African meningitis belt. Data on the safety and …

This report updates the 2004 recommendations by the Advisory Committee on Immunization
Practices (ACIP) regarding the use of influenza vaccine and antiviral agents (CDC …

The immunogenicity of polysaccharides as human vaccines was enhanced by coupling to
protein carriers. Conjugation transformed the T cell-independent polysaccharide vaccines of …

Glycoconjugate vaccines provide effective prophylaxis against bacterial infections. To date,
however, no commercial vaccine has been available in which the key carbohydrate antigens …

The meningococcal serogroup C conjugate (MCC) vaccine programme in England has
successfully controlled the incidence of serogroup C disease, as a result of high short-term …

Sepsis and meningitis caused by serogroup B meningococcus are devastating diseases of
infants and young adults, which cannot yet be prevented by vaccination. By genome mining …

A unique multicomponent vaccine against serogroup B meningococci incorporates the novel
genome-derived proteins fHbp, NHBA, and NadA that may vary in sequence and level of …

The introduction of meningococcal C conjugate (MCC) vaccine in the UK in November 1999
as a routine 3 dose infant immunisation course, with a single catch-up dose for all children …